Ollin Biosciences Announces $330M Series B to Accelerate OLN324 for DME and Wet AMD
AUSTIN, TX, June 24, 2026 Ollin Biosciences has announced the successful completion of an oversubscribed $330 million Series B...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
AUSTIN, TX, June 24, 2026 Ollin Biosciences has announced the successful completion of an oversubscribed $330 million Series B...
Mumbai, India and Naples, Florida, June 5, 2026 Global pharmaceutical company Lupin Limited has secured a major regulatory milestone...
BEDFORD, Mass., April 13, 2026 Ocular Therapeutix, Inc. has reported positive Week 52 data from its Phase 3 SOL-1...
TARRYTOWN, N.Y., April 2, 2026 Regeneron Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
INCHEON, South Korea, Oct. 9, 2025 — Celltrion, Inc., a global biopharmaceutical innovator, announced that the U.S. Food and...
